Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of chemotherapy-free copanlisib + obinutuzumab in previously untreated high-tumor-burden follicular lymphoma
2018-004038-13Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib and obinutuzumab in follicular lymphoma (FL), sponsored by LMU Klinikum. Primary endpoint: One-year progression-free survival probability. Started Feb 2020; status: completed.
02
Drugs
copanlisibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2018-004038-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004038-13.